In the February 23, 2009, issue of the Archives, Christen et al1 reported the results of a large clinical trial evaluating the effects of a combination of folic acid, pyridoxine hydrochloride (vitamin B6), and cyanocobalamin (vitamin B12) on the development of age-related macular degeneration (AMD). This report, the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS), was derived from the larger, previously published Women's Antioxidant Cardiovascular Study (WACS), which initially enrolled 8171 female participants (mean [SD] age, 62.8 [8.8] years) with preexisting cardiovascular disease (CVD) or 3 or more coronary risk factors to investigate the efficacy of ascorbic acid (vitamin C), vitamin E, beta carotene, or placebo on cardiovascular outcomes.2,3